首页 | 本学科首页   官方微博 | 高级检索  
     

双J管联合坦索罗辛在盆腔肿瘤治疗中预防输尿管副损伤的意义
引用本文:曾永威,高婉仪,唐照方,廖敏仪,秦福杰,李玉香,崔哲,卢桂尧,林伟广,唐廷勇. 双J管联合坦索罗辛在盆腔肿瘤治疗中预防输尿管副损伤的意义[J]. 安徽医药, 2021, 25(8): 1660-1663. DOI: 10.3969/j.issn.1009-6469.2021.08.043
作者姓名:曾永威  高婉仪  唐照方  廖敏仪  秦福杰  李玉香  崔哲  卢桂尧  林伟广  唐廷勇
作者单位:佛山市三水区人民医院泌尿外科,广东 佛山528100;佛山市三水区人民医院超声科,广东 佛山528100;佛山市三水区人民医院骨外科,广东 佛山528100;佛山市三水区人民医院妇科,广东 佛山528100;佛山市三水区人民医院肿瘤科,广东 佛山528100;佛山市三水区人民医院普通外科,广东 佛山528100
基金项目:佛山市医学类科技攻关项目( 2018AB001585)
摘    要:目的 探讨双J管联合坦索罗辛在盆腔肿瘤治疗中预防输尿管副损伤的应用意义.方法 选取2010年10月至2019年9月佛山市三水区人民医院盆腔肿瘤手术病人404例,分为预置管组120例,未置管组246例,单纯口服坦索罗辛组38例.预置管组术前膀胱镜下输尿管逆行插管留置双J管并保留至术后盆腔放疗结束,联合口服坦索罗辛缓释胶囊...

关 键 词:辐射损伤  双J管  坦索罗辛  盆腔肿瘤  输尿管副损伤

Application of double J tube combined with tamsulosin in the prevention of ureteral injury in the treatment of pelvic tumor
ZENG Yongwei,GAO Wanyi,TANG Zhaofang,LIAO Minyi,QIN Fujie,LI Yuxiang,CUI Zhe,LU Guiyao,LIN Weiguang,TANG Tingyong. Application of double J tube combined with tamsulosin in the prevention of ureteral injury in the treatment of pelvic tumor[J]. Anhui Medical and Pharmaceutical Journal, 2021, 25(8): 1660-1663. DOI: 10.3969/j.issn.1009-6469.2021.08.043
Authors:ZENG Yongwei  GAO Wanyi  TANG Zhaofang  LIAO Minyi  QIN Fujie  LI Yuxiang  CUI Zhe  LU Guiyao  LIN Weiguang  TANG Tingyong
Affiliation:Department of Urology,Foshan,Guangdong 528100, China;Department of Ultrasound,Foshan,Guangdong 528100, China;Department of Orthopeadic Surgery,Foshan,Guangdong 528100, China;Department of Gynaecology,Foshan,Guangdong 528100, China;Department of Internal Medicine-Oncology,Foshan,Guangdong 528100, China; Department of General Surgery, Sanshui District People''s Hospital of Foshan, Foshan,Guangdong 528100, China
Abstract:Objective To explore the clinical significance of double-J tube combined with tamsulosin in the prevention of ureteral injury in the treatment of pelvic tumor.Methods A total of 404 patients undergoing pelvic tumor surgery in Sanshui District People''sHospital of Foshan City from October 2010 to September 2019 were selected. The patients were assigned into preset tube group (n = 120), non-tube group (n = 246) and oral tamsulosin group (n = 38). In the preset tube group, double-J tube was indwelling through retrograde ureteral intubation under cystoscope before operation and double-J tube was retained until the end of postoperative pelvic radiotherapy, combined with oral tamsulosin sustained-release capsule. There was no double-J tube in the group without catheterization. In the tamsulosin group, tamsulosin sustained-release capsules were taken after pelvic tumor surgery. The clinical data, intraoperative ureteral injury and postoperative radiotherapy complications of the three groups were compared.Results There were 2 (1.67%) cases of ureteral injury in the preset tube group and 13 (5.28%) cases of ureteral injury in the non-catheterized group, and the difference of injury rate between the two groups was statistically significant (P < 0.05). After postoperative radiotherapy in the three groups, 2 of 89 patients (2.25%) in the preset tube group, 22 of 162 patients (13.58%) in the non-tube group, and 6 of 38 patients (15.79%) in the orallyadministered tamsulosin group developed ureteral stricture resulting in renal function impairment. The incidence of postoperative radiotherapy complications in the preset tube group was compared with that in the other two groups. The difference was statistically significant (P < 0.05).Conclusion Combined use of double-J tube tamsulosin in pelvic tumor surgery has important significance to improvethe identification of ureter, reduce ureteral injury and postoperative ureteral fibrosis stenosis, reduce the risk of renal function injury caused by radioactive ureteral stenosis, reduce the symptoms of urinary tract irritation caused by indwelling double-J tube, promote the recovery of ureteral injury, and protect renal function.
Keywords:Radiation injuries   Double-J tube   Tamsulosin   Pelvic tumors   Ureteral injury
本文献已被 万方数据 等数据库收录!
点击此处可从《安徽医药》浏览原始摘要信息
点击此处可从《安徽医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号